XTL Biopharmaceuticals Ltd. (XTLB) Price

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The firm's pipelines include hCDR1 for systemic lupus erythematosus and recombinant human erythropoietin (rHuEPO) for multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS), is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO is a known agent for anemia and helps prolong the survival of patients in the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythoid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.